Effect of Complement CR1 on Brain Amyloid Burden During Aging and Its Modification by APOE Genotype

[1]  Thomas W. Mühleisen,et al.  Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease , 2013, Nature Genetics.

[2]  Michelle K. Lupton,et al.  Complement activation as a biomarker for Alzheimer's disease. , 2012, Immunobiology.

[3]  F. Pasquier,et al.  Alzheimer risk associated with a copy number variation in the complement receptor 1 increasing C3b/C4b binding sites , 2011, Molecular Psychiatry.

[4]  Christos Davatzikos,et al.  Lack of association between 11C-PiB and longitudinal brain atrophy in non-demented older individuals , 2011, Neurobiology of Aging.

[5]  Michael W. Weiner,et al.  Amyloid pathway-based candidate gene analysis of [11C]PiB-PET in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort , 2011, Brain Imaging and Behavior.

[6]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.

[7]  A. Ruiz,et al.  Genetic association of complement receptor 1 polymorphism rs3818361 in Alzheimer’s disease , 2011, Alzheimer's & Dementia.

[8]  Jason J. Corneveaux,et al.  CR1 is associated with amyloid plaque burden and age‐related cognitive decline , 2011, Annals of neurology.

[9]  A. Fagan,et al.  Fine Mapping of Genetic Variants in BIN1, CLU, CR1 and PICALM for Association with Cerebrospinal Fluid Biomarkers for Alzheimer's Disease , 2011, PloS one.

[10]  Todd E. Golde,et al.  Anti-Aβ Therapeutics in Alzheimer's Disease: The Need for a Paradigm Shift , 2011, Neuron.

[11]  C. Rowe,et al.  Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease , 2011, Annals of neurology.

[12]  V Shane Pankratz,et al.  Replication of BIN1 association with Alzheimer's disease and evaluation of genetic interactions. , 2011, Journal of Alzheimer's disease : JAD.

[13]  L. Ferrucci,et al.  Proteome-based plasma markers of brain amyloid-β deposition in non-demented older individuals. , 2011, Journal of Alzheimer's disease : JAD.

[14]  K. Lunetta,et al.  Meta-analysis confirms CR1, CLU, and PICALM as alzheimer disease risk loci and reveals interactions with APOE genotypes. , 2010, Archives of neurology.

[15]  Kewei Chen,et al.  Association of CR1, CLU and PICALM with Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals. , 2010, Human molecular genetics.

[16]  V. Pankratz,et al.  Replication of CLU, CR1, and PICALM associations with alzheimer disease. , 2010, Archives of neurology.

[17]  Sudha Seshadri,et al.  Genome-wide analysis of genetic loci associated with Alzheimer disease. , 2010, JAMA.

[18]  W. Jagust,et al.  The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core , 2010, Alzheimer's & Dementia.

[19]  J. Morris,et al.  Clinical core of the Alzheimer's disease neuroimaging initiative: Progress and plans , 2010, Alzheimer's & Dementia.

[20]  Jason H. Moore,et al.  Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans , 2010, Alzheimer's & Dementia.

[21]  L. Ferrucci,et al.  Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB , 2010, Neurology.

[22]  P. Tariot,et al.  Alzheimer's prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible. , 2010, Biomarkers in medicine.

[23]  Luigi Ferrucci,et al.  Variants of the serotonin transporter gene and NEO‐PI‐R Neuroticism: No association in the BLSA and SardiNIA samples , 2009, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[24]  L. Kiemeney,et al.  Corrigendum: Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer , 2009, Nature Genetics.

[25]  P. Bosco,et al.  Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease , 2009, Nature Genetics.

[26]  G. Alexander,et al.  Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease , 2009, Proceedings of the National Academy of Sciences.

[27]  Susan M Resnick,et al.  Longitudinal Cerebral Blood Flow and Amyloid Deposition: An Emerging Pattern? , 2008, Journal of Nuclear Medicine.

[28]  Yun Zhou,et al.  Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease , 2007, NeuroImage.

[29]  P. Mcgeer,et al.  Inflammation, the complement system and the diseases of aging , 2005, Neurobiology of Aging.

[30]  S. DeKosky,et al.  Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[31]  R. Petersen.  Mild cognitive impairment as a diagnostic entity , 2004, Journal of internal medicine.

[32]  S. Chien,et al.  National Institute of Biomedical Imaging and Bioengineering , 2020, Definitions.

[33]  Hyoung-Gon Lee,et al.  Challenging the Amyloid Cascade Hypothesis: Senile Plaques and Amyloid‐β as Protective Adaptations to Alzheimer Disease , 2004, Annals of the New York Academy of Sciences.

[34]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[35]  S. Resnick,et al.  One-year age changes in MRI brain volumes in older adults. , 2000, Cerebral cortex.

[36]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[37]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.

[38]  D. T. Vernier,et al.  Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. , 1990, Journal of lipid research.

[39]  R. Mohs,et al.  Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. , 2002, Psychopharmacology bulletin.